Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Anand Patel, Theodore Karrison, Emily Dworkin, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Caner Saygin, Mariam Nawas, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Wendy Stock, Richard Larson, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 5608.

https://doi.org/10.1182/blood-2025-5608

Published: 2025

Journal Articles

Phase II trial of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone in multiple myeloma following BCMA CAR T-cell therapy

Benjamin Derman, Jennifer Cooperrider, Frank Wen, Anna Pula, Ken Jiang, Theodore Karrison, Andrzej Jakubowiak

Blood (2025) 146 (Supplement 1): 5832.

https://doi.org/10.1182/blood-2025-5832

Published: 2025

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) – interim results from the randomized Phase III COBRA trial.

Blood (2025) 146 (Supplement 1): 99.

https://doi.org/10.1182/blood-2025-99

Published: 2025

Journal Articles

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Anand Patel, Michael Drazer, Theodore Karrison, Lorraine Pelosof, Steven Gore, Richard Little, Alexey Danilov, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 3827.

https://doi.org/10.1182/blood-2025-3827

Published: 2025

Journal Articles

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Blood (2025) 146 (Supplement 1): 441.

https://doi.org/10.1182/blood-2025-441

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Anand Ashwin Patel, Adam S. Duvall, Caner Saygin, Howard Weiner, Emily Dworkin, Afsheen Noorani, Jamie Matthews, Rafael Madero Marroquin, Michael W Drazer, Mariam T. Nawas, Gregory W Roloff, Satyajit Kosuri, Michael J. Thirman, Richard A. Larson, Olatoyosi Odenike, Theodore Karrison, Wendy Stock

Blood (2024) 144 (Supplement 1): 1432.

https://doi.org/10.1182/blood-2024-193442

Published: 2024

Journal Articles

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Benjamin A Derman, Jennifer H Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Ajay Major, Theodore Karrison, Ken Jiang, Tadeusz Kubicki, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2023-185309

Published: 2023

Journal Articles

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman, Tadeusz Kubicki, Heidi Simmons, Aimaz Afrough, Jeffrey A. Zonder, David L. Grinblatt, Larry D. Anderson, Jr., Andrew Kin, Sunil Narula, Shayan Rayani, Sandeep Gurbuxani, Theodore Karrison, Ken Jiang, Ajay Major, Jennifer H Cooperrider, Allison P. Jacob, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2023-182410

Published: 2023

Journal Articles

Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Andrzej Jakubowiak, MDPhD, Jagoda Jasielec, MD, Cara A. Rosenbaum, MD, Craig E. Cole, MD, Ajai Chari, MD, Jennifer Nam, Erica Severson, Leonor A Stephens, PhD, Kathryn McDonnell, Shaun Rosebeck, PhD, Todd Zimmerman, MD, Theodore Karrison, PhD, Jeffrey Zonder, MD

Blood (2016) 128 (22): 973.

https://doi.org/10.1182/blood.V128.22.973.973

Published: 2016

Journal Articles

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Justin Kline, MD, Aaron P. Rapoport, MD, Adam M. Petrich, MD, Kenneth S. Cohen, MD, Sachdev P. Thomas, MD, Sreenivasa Nattam, MD, Krishna Rao, MD, Bethany Sleckman, MD, Walter Stadler, MD, Theodore Karrison, PhD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4147.

https://doi.org/10.1182/blood.V128.22.4147.4147

Published: 2016

Journal Articles

Prospective Phase I Multi-Center Trial Incorporating Lenalidomide (LEN) into Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Patients with Double Hit (DHL) or Double Expressing (DEL) Lymphomas: Final Results

Chadi Nabhan, MD MBA, FACP, Theodore Karrison, PhD, Justin Kline, Kenneth Cohen, MD, Michael R. Bishop, MD, Reem Karmali, MD MS, Aaron P. Rapoport, MD, Parameswaran Venugopal, MD, James Wade, MD, Paul Fishkin, MD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4191.

https://doi.org/10.1182/blood.V128.22.4191.4191

Published: 2016

Journal Articles

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Natalie Galanina, MD, Sonali M. Smith, MD, Chuanhong Liao, PhD, Adam M. Petrich, MD, Bernadette Libao, Ron Gartenhaus, MD, Jason R Westin, MD, Kenneth S. Cohen, MD, James Knost, MD, Walter Stadler, MD, Austin Doyle, MD, Theodore Karrison, PhD, Leo I. Gordon, MD, Andrew M Evens, DO, MS

Blood (2015) 126 (23): 3990.

https://doi.org/10.1182/blood.V126.23.3990.3990

Published: 2015

Journal Articles

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Cara A. Rosenbaum, MD, Jeffrey A Zonder, MD, Craig E. Cole, MD, Ajai Chari, MD, Jennifer Nam, Leonor A Stephens, PhD, Kathryn McDonnell, Rebecca Uribe, Shaun Rosebeck, PhD, Tami Rashal, MD, Hagop Youssoufian, MD, Sarah Henry, Sharon Shacham, Michael Kauffman, MD PhD, Todd Zimmerman, MD, Theodore Karrison, PhD

Blood (2015) 126 (23): 4223.

https://doi.org/10.1182/blood.V126.23.4223.4223

Published: 2015

Journal Articles

Haploinsufficiency of del(5q) genes, Egr1 and Apc , cooperate with Tp53 loss to induce acute myeloid leukemia in mice

Angela Stoddart, Anthony A. Fernald, Jianghong Wang, Elizabeth M. Davis, Theodore Karrison, John Anastasi, Michelle M. Le Beau

Blood (2014) 123 (7): 1069–1078.

https://doi.org/10.1182/blood-2013-07-517953

Published: 2014

Includes: Supplemental data

Journal Articles

Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc

Angela Stoddart, Jianghong Wang, Anthony A. Fernald, Theodore Karrison, John Anastasi, Michelle M. Le Beau

Blood (2014) 123 (2): 228–238.

https://doi.org/10.1182/blood-2013-05-506568

Published: 2014

Includes: Supplemental data

Journal Articles

Retroviral Insertional Mutagenesis In Egr1 +/- mice, Haploinsufficient For a Human Del(5q) Myeloid Leukemia Gene, Develop Myeloid Neoplasms With Proviral Insertions In Genes Syntenic To Human 5q

Angela Stoddart, PhD, Anthony Fernald, Rachel Joy Bergerson, PhD, Jianghong Wang, M.D., Megan E. McNerney, MD, PhD, Theodore Karrison, Ph.D., John Anastasi, MD, Elizabeth Bartom, Ph.D., Aaron G. Sarver, Ph.D., Zhijian Qian, PhD, Linda Wolff, PhD, David A. Largaespada, PhD, Michelle M. le Beau, PhD

Blood (2013) 122 (21): 1275.

https://doi.org/10.1182/blood.V122.21.1275.1275

Published: 2013

Journal Articles

Identification of High Risk HLA Class I Amino Acid Substitutions in Hematopoietic Stem Cell Transplantation.

Susana R Marino, MD, PhD, Sang M Lee, PhD, T Andrew Binkowski, PhD, Michael D Haagenson, MS, Martin Maiers, PhD, Stephen Spellman, MBS, Koen van Besien, MD, Stephanie J Lee, MD, MPH, Theodore Karrison, PhD, Andrew Artz, MD MS

Blood (2012) 120 (21): 3050.

https://doi.org/10.1182/blood.V120.21.3050.3050

Published: 2012

Journal Articles

Therapy-Related Myeloid Neoplasms (t-MN) in 71 Patients Following Radiation Therapy (RT) Only,

Richard J Lin, M.D., Smita Joshi, M.D., Michelle M. Le Beau, PhD, Howard Weiner, Peggy Green, RN, Theodore Karrison, Ph.D., Richard A. Larson, MD

Blood (2011) 118 (21): 3522.

https://doi.org/10.1182/blood.V118.21.3522.3522

Published: 2011

Journal Articles

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Elizabeth Shima Rich, MD, PhD, Andrew Artz, MD, MS, Theodore Karrison, Ph.D., Lucy A Godley, MD, PhD, Olatoyosi Odenike, MD, Loren Joseph, MD, Justin Kline, MD, Vu H. Nguyen, MD, Guadalupe Martinez, BS, Paula del Cerro, RN, Lisa Pape, RN, Linda Schroeder, RN, Scott Allen, BA, Sarah Horowitz, BA, John Cunningham, MD, Richard A. Larson, MD, Wendy Stock, MD, Amittha Wickrema, PhD, Koen van Besien, MD

Blood (2009) 114 (22): 3378.

https://doi.org/10.1182/blood.V114.22.3378.3378

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Phase II trial of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone in multiple myeloma following BCMA CAR T-cell therapy

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) – interim results from the randomized Phase III COBRA trial.

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Prospective Phase I Multi-Center Trial Incorporating Lenalidomide (LEN) into Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Patients with Double Hit (DHL) or Double Expressing (DEL) Lymphomas: Final Results

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Haploinsufficiency of del(5q) genes, Egr1 and Apc , cooperate with Tp53 loss to induce acute myeloid leukemia in mice

Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc

Retroviral Insertional Mutagenesis In Egr1 +/- mice, Haploinsufficient For a Human Del(5q) Myeloid Leukemia Gene, Develop Myeloid Neoplasms With Proviral Insertions In Genes Syntenic To Human 5q

Identification of High Risk HLA Class I Amino Acid Substitutions in Hematopoietic Stem Cell Transplantation.

Therapy-Related Myeloid Neoplasms (t-MN) in 71 Patients Following Radiation Therapy (RT) Only,

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only